2010
When Is Door-to-Balloon Time Critical? Analysis From the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trials
Brodie BR, Gersh BJ, Stuckey T, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Grines CL, Cox D, Parise H, Prasad A, Lansky AJ, Mehran R, Stone GW. When Is Door-to-Balloon Time Critical? Analysis From the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trials. Journal Of The American College Of Cardiology 2010, 56: 407-413. PMID: 20650362, DOI: 10.1016/j.jacc.2010.04.020.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionLower mortality rateHigh-risk patientsPercutaneous coronary interventionMortality rateEarly presentationCoronary interventionClinical riskST-segment elevation myocardial infarctionSimilar relative risk reductionsHORIZONS-AMI trialElevation myocardial infarctionRelative risk reductionNon-percutaneous coronary intervention hospitalsMortality rate reductionImpact of doorCADILLAC trialHORIZONS-AMIAntithrombotic therapyReperfusion therapyBalloon timeIntervention hospitalsAbsolute benefitLate presentationMyocardial infarction
2009
Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction
RABBANI LE, IYENGAR S, DANGAS GD, GRINES CL, COX DA, GARCIA E, TCHENG JE, GRIFFIN JJ, GUAGLIUMI G, STUCKEY T, TURCO M, STANT J, FAHY M, LANSKY AJ, MEHRAN R, STONE GW. Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction. Journal Of Interventional Cardiology 2009, 22: 378-384. PMID: 19496901, DOI: 10.1111/j.1540-8183.2009.00474.x.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAspirinConfidence IntervalsDrug Therapy, CombinationDrug-Eluting StentsFemaleHumansImmunoglobulin Fab FragmentsKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial RevascularizationOdds RatioPlatelet Aggregation InhibitorsPreoperative CarePyridinesTime FactorsConceptsMajor adverse cardiovascular eventsAcute myocardial infarctionTarget vessel revascularizationIschemic target vessel revascularizationPrimary stentingThienopyridine administrationLoading doseTH patientsStent implantationMyocardial infarctionClopidogrel loading doseAdverse cardiovascular eventsSuperior clinical outcomesBare-metal stentingAbciximab useCADILLAC trialCardiovascular eventsVessel revascularizationClinical outcomesMetal stentingProcedural characteristicsOperator's discretionPatientsStentingCore labPrognostic Impact of Blood Transfusion After Primary Angioplasty for Acute Myocardial Infarction Analysis From the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial
Nikolsky E, Mehran R, Sadeghi HM, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Stone GW. Prognostic Impact of Blood Transfusion After Primary Angioplasty for Acute Myocardial Infarction Analysis From the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. JACC Cardiovascular Interventions 2009, 2: 624-632. PMID: 19628185, DOI: 10.1016/j.jcin.2009.05.004.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAge FactorsAgedAnemiaAngioplasty, Balloon, CoronaryAntibodies, MonoclonalErythrocyte TransfusionFemaleHeart DiseasesHumansImmunoglobulin Fab FragmentsKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionOdds RatioPlatelet Aggregation InhibitorsProportional Hazards ModelsProspective StudiesRadiographyRecurrenceRisk AssessmentRisk FactorsSeverity of Illness IndexSex FactorsStrokeTime FactorsTreatment OutcomeConceptsPrimary percutaneous coronary interventionAcute myocardial infarctionPrimary PCIRBC transfusionCADILLAC trialClinical outcomesComposite major adverse cardiac eventsAcute Myocardial Infarction AnalysisMajor adverse cardiac eventsCoronary artery bypass surgeryRed blood cell transfusionMechanical reperfusion therapyAdverse cardiac eventsArtery bypass surgeryBlood cell transfusionTriple vessel diseasePercutaneous coronary interventionBaseline anemiaMajor bleedingTransfusion propensityCell transfusionIndex hospitalizationMultivariable adjustmentPrimary angioplastyReperfusion therapy
2008
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial
Lansky AJ, Tsuchiya Y, Brener M, Mehran R, Cristea E, Pietras C, Grines CL, Cox DA, Garcia E, Tcheng JE, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Leon MB, Moses J, Stone GW. Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial. Catheterization And Cardiovascular Interventions 2008, 72: 917-924. PMID: 19016469, DOI: 10.1002/ccd.21714.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAspirinClopidogrelCoronary AngiographyDrug Therapy, CombinationEuropeFemaleHemorrhageHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionMyocardial IschemiaPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicRetrospective StudiesRisk AssessmentStentsThrombosisTiclopidineTime FactorsTreatment OutcomeUnited StatesConceptsAcute myocardial infarctionPrimary stentingCADILLAC trialRecurrent ischemiaSevere bleedingMyocardial infarctionEfficacy of clopidogrelMore recurrent ischemiaTIMI 0/1 flowSimilar clinical outcomesTiclopidine treatmentAngiographic characteristicsClopidogrel useIndependent predictorsClinical outcomesMultivariable analysisRandomized trialsStent thrombosisStent implantationOperator's discretionClopidogrelStentingPatientsTiclopidineRelative safety
2007
Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction
Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, Stuckey T, Tcheng JE, Mehran R, Lansky AJ, Grines CL, Stone GW. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. European Heart Journal 2007, 28: 1709-1716. PMID: 17556348, DOI: 10.1093/eurheartj/ehm184.Peer-Reviewed Original ResearchConceptsPrimary PCIPrimary percutaneous coronary interventionMajor adverse cardiac eventsAcute myocardial infarctionCoronary artery diseaseTriple vessel diseasePercutaneous coronary interventionMultivessel diseaseST-segment recoveryReperfusion successCoronary interventionClinical outcomesMyocardial blushMyocardial infarctionPost-procedural TIMI 3 flowExtent of CADExtensive coronary artery diseaseMultivessel coronary artery diseaseAdverse cardiac eventsTIMI 3 flowInfarct-related arterySingle-vessel diseaseCADILLAC trialPost-PCIInfarct vesselImpact of Baseline Platelet Count in Patients Undergoing Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (from the CADILLAC Trial)
Nikolsky E, Grines CL, Cox DA, Garcia E, Tcheng JE, Sadeghi M, Mehran R, Lansky AJ, Na Y, Stone GW. Impact of Baseline Platelet Count in Patients Undergoing Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (from the CADILLAC Trial). The American Journal Of Cardiology 2007, 99: 1055-1061. PMID: 17437727, DOI: 10.1016/j.amjcard.2006.11.066.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCause of DeathCoronary AngiographyCoronary RestenosisCoronary ThrombosisCreatine KinaseFemaleFollow-Up StudiesForecastingHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPlatelet CountPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecurrenceStentsTreatment OutcomeConceptsPrimary percutaneous coronary interventionBaseline platelet countAcute myocardial infarctionPrimary PCIHigher baseline platelet countPercutaneous coronary interventionPlatelet countCoronary interventionMyocardial infarctionAngiographic success rateTarget vessel thrombosisPowerful independent predictorMedian platelet countRole of plateletsCADILLAC trialCardiac mortalityAngiographic outcomesIndependent predictorsAngiographic resultsHighest quartileMultivariable analysisVessel thrombosisVascular responsesReinfarctionPatientsRelation Between Leucocyte Count, Myonecrosis, Myocardial Perfusion, and Outcomes Following Primary Angioplasty
Prasad A, Stone GW, Stuckey TD, Costantini CO, Mehran R, Garcia E, Tcheng JE, Cox DA, Grines CL, Lansky AJ, Gersh BJ. Relation Between Leucocyte Count, Myonecrosis, Myocardial Perfusion, and Outcomes Following Primary Angioplasty. The American Journal Of Cardiology 2007, 99: 1067-1071. PMID: 17437729, DOI: 10.1016/j.amjcard.2006.11.063.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAngioplasty, Balloon, CoronaryCoronary AngiographyCoronary CirculationCreatine KinaseFemaleForecastingHumansLeukocyte CountLeukocytosisMaleMicrocirculationMiddle AgedMyocardial InfarctionMyocardial ReperfusionProspective StudiesRetrospective StudiesSmokingSurvival RateTreatment OutcomeConceptsPrimary percutaneous coronary interventionPrimary PCIBaseline leukocyte countAcute myocardial infarctionHigh leukocyte countLeukocyte countMyocardial perfusionMyocardial blush grade 2/3Myocardial infarction (TIMI) flowMyocardial blush gradePredictors of mortalityPercutaneous coronary interventionNegative prognostic factorPeak creatine phosphokinaseBaseline leukocytosisCADILLAC trialBlush gradePrimary angioplastyCoronary interventionCurrent smokersIndependent predictorsPrognostic factorsReperfusion successClinical outcomesGrade 2/3
2006
Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: Analysis from the CADILLAC trial
Brodie BR, Stone GW, Cox DA, Stuckey TD, Turco M, Tcheng JE, Berger P, Mehran R, McLaughlin M, Costantini C, Lansky AJ, Grines CL. Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: Analysis from the CADILLAC trial. American Heart Journal 2006, 151: 1231-1238. PMID: 16781224, DOI: 10.1016/j.ahj.2005.07.016.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionPercutaneous coronary interventionAcute myocardial infarctionLow-risk patientsLeft ventricular functionOnset of symptomsTreatment delayCoronary interventionEarly reperfusionMyocardial infarctionCADILLAC trialVentricular functionComplete ST-segment resolutionPercutaneous transluminal coronary angioplastyFrequent grade 2ST-segment resolutionHigh-risk patientsSuperior clinical outcomesTransluminal coronary angioplastyMicrovascular reperfusionBalloon timeCoronary angioplastyClinical outcomesMyocardial blushPatient triageImpact of body mass index on outcomes after primary angioplasty in acute myocardial infarction
Nikolsky E, Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Negoita M, Lansky AJ, Mehran R. Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction. American Heart Journal 2006, 151: 168-175. PMID: 16368312, DOI: 10.1016/j.ahj.2005.03.024.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionPrimary PCIBody mass indexAcute myocardial infarctionNormal weight patientsBaseline body mass indexObese patientsMyocardial infarctionCreatinine clearanceMass indexNon-anterior myocardial infarctionAnterior acute myocardial infarctionLower inhospital mortalityGood renal functionHigher creatinine clearanceLower creatinine clearanceBlood product transfusionLow ejection fractionPercutaneous coronary interventionCADILLAC trialHours onsetInhospital mortalityHemorrhagic complicationsPrimary angioplastyProduct transfusion
2005
Impact of In-Hospital Acquired Thrombocytopenia in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction
Nikolsky E, Sadeghi HM, Effron MB, Mehran R, Lansky AJ, Na Y, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Stuckey TD, Turco M, Carroll JD, Grines CL, Stone GW. Impact of In-Hospital Acquired Thrombocytopenia in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction. The American Journal Of Cardiology 2005, 96: 474-481. PMID: 16098296, DOI: 10.1016/j.amjcard.2005.04.005.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAge DistributionAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCause of DeathFemaleFollow-Up StudiesHemorrhageHumansImmunoglobulin Fab FragmentsIncidenceInpatientsMaleMiddle AgedMyocardial InfarctionOdds RatioPlatelet Aggregation InhibitorsPlatelet CountProspective StudiesRisk FactorsSex DistributionSurvival RateThrombocytopeniaTreatment OutcomeConceptsPrimary percutaneous coronary interventionPercutaneous coronary interventionAcute myocardial infarctionHemorrhagic complicationsAcquired thrombocytopeniaPlatelet countMyocardial infarctionHigher baseline platelet countGreater body mass indexNadir platelet countPrevious aspirin useUse of abciximabBaseline platelet countBlood product transfusionLonger hospital stayMajor hemorrhagic complicationsHours of onsetBody mass indexAspirin useBaseline thrombocytopeniaCADILLAC trialIschemic complicationsCause mortalityHospital stayPrimary angioplastyImpact and Determinants of Left Ventricular Function in Patients Undergoing Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction
Halkin A, Stone GW, Dixon SR, Grines CL, Tcheng JE, Cox DA, Garcia E, Brodie B, Stuckey TD, Mehran R, Lansky AJ. Impact and Determinants of Left Ventricular Function in Patients Undergoing Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. The American Journal Of Cardiology 2005, 96: 325-331. PMID: 16054451, DOI: 10.1016/j.amjcard.2005.03.069.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionLeft ventricular functionBaseline left ventricular functionPrimary angioplastyBaseline LVEFVentricular functionIndependent predictorsIndex procedureMyocardial infarctionInfarct zone regional wall motionBaseline left ventricular dysfunctionMyocardial Infarction grade 0Primary percutaneous coronary interventionOne-year survival ratePrevious acute myocardial infarctionMultivessel coronary diseaseLeft ventricular dysfunctionPercutaneous coronary interventionVentricular ejection fractionStrong independent predictorRegional wall motionCADILLAC trialPreprocedural ThrombolysisVentricular dysfunctionCoronary interventionImpact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction—The smoker's paradox revisited
Weisz G, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey TD, Rutherford BD, Mehran R, Aymong E, Lansky A, Grines CL, Stone GW. Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction—The smoker's paradox revisited. American Heart Journal 2005, 150: 358-364. PMID: 16086943, DOI: 10.1016/j.ahj.2004.01.032.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAnticoagulantsComorbidityCoronary AngiographyFemaleFollow-Up StudiesHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMortalityMyocardial InfarctionPlatelet Aggregation InhibitorsProspective StudiesRecurrenceRiskSmokingSmoking CessationStentsStrokeSurvival AnalysisTreatment OutcomeConceptsAcute myocardial infarctionSmoking statusCurrent smokersSmoker's paradoxCoronary interventionFormer smokersCigarette smokingMyocardial infarctionPrior acute myocardial infarctionPrimary percutaneous coronary interventionPercutaneous transluminal coronary angioplastyTriple-vessel coronary diseaseMechanical reperfusion therapyPrimary coronary interventionProcedural success ratePercutaneous coronary interventionTransluminal coronary angioplastyAge-adjusted riskCurrent smoking statusOccurrence of AMITime of presentationLower mortality rateCADILLAC trialLate mortalityPrimary PCIGender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction
Lansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, Aymong ED, Stuckey TD, Garcia E, Tcheng JE, Mehran R, Negoita M, Fahy M, Cristea E, Turco M, Leon MB, Grines CL, Stone GW. Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction. Circulation 2005, 111: 1611-1618. PMID: 15811868, DOI: 10.1161/01.cir.0000160362.55803.40.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionPrimary stentingAddition of abciximabBody surface areaCADILLAC trialMyocardial infarctionRisk factorsFemale genderIschemic target vessel revascularizationLower body surface areaMajor adverse cardiac eventsOverall adverse outcomesTIMI grade 3Adverse cardiac eventsTarget vessel revascularizationClinical risk factorsComorbid risk factorsInterventional treatment strategiesImportant independent determinantHigh mortality rateMACE ratePrimary angioplastyCardiac eventsSymptom onsetIndependent predictorsCombined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction
Sorajja P, Gersh BJ, Costantini C, McLaughlin MG, Zimetbaum P, Cox DA, Garcia E, Tcheng JE, Mehran R, Lansky AJ, Kandzari DE, Grines CL, Stone GW. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. European Heart Journal 2005, 26: 667-674. PMID: 15734768, DOI: 10.1093/eurheartj/ehi167.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionAcute myocardial infarctionPrimary PCIPercutaneous coronary interventionST-segment recoveryMyocardial blushCoronary interventionMultivariable analysisPrognostic utilityMyocardial infarctionGreater prognostic utilityStrongest prognostic variableYear clinical outcomesIncremental prognostic informationCADILLAC trialReperfusion therapyReperfusion successClinical outcomesGrade 2/3Independent correlatesMicrocirculatory integrityPrognostic informationUnivariate analysisPoor survivalCumulative rate
2004
Outcome in Elderly Patients Undergoing Primary Coronary Intervention for Acute Myocardial Infarction
Guagliumi G, Stone GW, Cox DA, Stuckey T, Tcheng JE, Turco M, Musumeci G, Griffin JJ, Lansky AJ, Mehran R, Grines CL, Garcia E. Outcome in Elderly Patients Undergoing Primary Coronary Intervention for Acute Myocardial Infarction. Circulation 2004, 110: 1598-1604. PMID: 15353506, DOI: 10.1161/01.cir.0000142862.98817.1f.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAdrenergic beta-AntagonistsAdultAge FactorsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAspirinCohort StudiesCombined Modality TherapyCoronary AngiographyCoronary RestenosisFemaleHemorrhageHumansImmunoglobulin Fab FragmentsLife TablesMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsProportional Hazards ModelsPyridinesStentsStrokeTreatment OutcomeConceptsAcute myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsElderly patientsPercutaneous coronary interventionMajor bleedingYears of ageCoronary interventionClinical outcomesStent implantationMyocardial infarctionPlatelet glycoprotein IIb/IIIa inhibitorsDecile of ageMechanical reperfusion strategiesOne-year mortalityPrimary coronary interventionRate of strokeCoronary stent implantationImpact of ageRate of mortalityAbciximab administrationCADILLAC trialReperfusion modalityTarget revascularizationMagnitude and impact of treatment delays on weeknights and weekends in patients undergoing primary angioplasty for acute myocardial infarction (the cadillac trial)
Sadeghi HM, Grines CL, Chandra HR, Mehran R, Fahy M, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Stuckey TD, Lansky AJ, O'Neill WW, Stone GW. Magnitude and impact of treatment delays on weeknights and weekends in patients undergoing primary angioplasty for acute myocardial infarction (the cadillac trial). The American Journal Of Cardiology 2004, 94: 637-640. PMID: 15342297, DOI: 10.1016/j.amjcard.2004.05.030.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionAcute myocardial infarctionMyocardial infarctionOutcomes of patientsCADILLAC trialPrimary angioplastyCoronary interventionProcedural successTreatment delayMyocardial recoveryPatientsModest delayInfarctionWeeknightsHoursTreatment timeAngioplastyWeekendsTrials801-3 Anemia worsens prognosis after primary angioplasty in acute myocardial infarction: Analysis from the CADILLAC trial
Nikolsky E, Halkin A, Aymong E, Mehran R, Lansky A, Grines C, Turco M, Cox D, Garcia E, Tcheng J, Griffin J, Guagliumi G, Stuckey T, Cohen D, Rutherford B, Stone G. 801-3 Anemia worsens prognosis after primary angioplasty in acute myocardial infarction: Analysis from the CADILLAC trial. Journal Of The American College Of Cardiology 2004, 43: a267. DOI: 10.1016/s0735-1097(04)91134-5.Peer-Reviewed Original Research869-1 Relationship between time to reperfusion, ST-segment resolution, myocardial blush scores and mortality with primary percutaneous coronary intervention for acute myocardial infarction: Results from the CADILLAC trial
Brodie B, Costantini C, Aymong E, Stuckey T, Cox D, Zimetbaum P, McLaughlin M, Garcia E, Turco M, Mehran R, Grines C, Lansky A, Stone G. 869-1 Relationship between time to reperfusion, ST-segment resolution, myocardial blush scores and mortality with primary percutaneous coronary intervention for acute myocardial infarction: Results from the CADILLAC trial. Journal Of The American College Of Cardiology 2004, 43: a303. DOI: 10.1016/s0735-1097(04)91283-1.Peer-Reviewed Original Research
2003
Outcomes following Bail-Out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial)
Ashby DT, Aymong EA, Tcheng JE, Grines CL, Cox DA, Mehran R, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Lansky AJ, Stone GW. Outcomes following Bail-Out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). The American Journal Of Cardiology 2003, 92: 1091-1094. PMID: 14583362, DOI: 10.1016/j.amjcard.2003.06.005.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCross-Over StudiesDrug Administration ScheduleFemaleFollow-Up StudiesHumansImmunoglobulin Fab FragmentsIntraoperative ComplicationsMaleMiddle AgedMyocardial InfarctionPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesTreatment FailureConceptsAcute myocardial infarctionMyocardial infarctionGlycoprotein IIb/IIIa receptor inhibitorsUnsuccessful primary percutaneous coronary interventionIIb/IIIa receptor inhibitorsMyocardial Infarction (TIMI) grade 3 flowPrimary percutaneous coronary interventionGrade 3 flowPercutaneous coronary interventionSuboptimal angioplasty resultsAbciximab administrationCADILLAC trialIschemic complicationsControl patientsCoronary interventionProcedural complicationsAngioplasty resultsReceptor inhibitorsPrimary interventionAbciximabPatientsComplicationsInfarctionLower ratesInterventionOutcomes of bail-out stenting for suboptimal balloon angioplasty during primary intervention in acute myocardial infarction (The CADILLAC trial)
Ashby DT, Aymong EA, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Carroll JD, Turco M, Lansky AJ, Stone GW. Outcomes of bail-out stenting for suboptimal balloon angioplasty during primary intervention in acute myocardial infarction (The CADILLAC trial). The American Journal Of Cardiology 2003, 92: 1095-1098. PMID: 14583363, DOI: 10.1016/j.amjcard.2003.06.006.Peer-Reviewed Original ResearchConceptsSuccessful balloon angioplastyAcute myocardial infarctionBalloon angioplastyRoutine stentingMyocardial infarctionEvent-free survivalPrimary balloon angioplastySuboptimal balloon angioplastyCADILLAC trialUnsuccessful dilatationPrimary interventionAngioplastyStentingInfarctionPatientsDilatationTrials